Biocon Biologics, a subsidiary of Biocon Ltd, has announced a partnership with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Program (PAP) aimed at improving access to affordable cancer treatment for underserved patients in Malaysia.
Under this collaboration, Biocon Biologics — a global leader in biosimilars — will provide essential oncology biosimilars, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to NCSM. The not-for-profit organization will manage patient enrollment and medicine distribution as part of its ongoing community outreach and healthcare support efforts.
Tackling Treatment Delays Due to Financial Barriers
The program will initially focus on providing Trastuzumab to patients facing financial challenges that prevent them from starting or continuing their cancer treatment. The initiative was formalized with the signing of a Memorandum of Understanding (MoU) during the National Cancer Congress Malaysia 2025 in Kuala Lumpur.
“This partnership represents a significant step in expanding access to high-quality oncology biosimilars for patients who need them most,” said Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics. “By combining Biocon Biologics’ scientific expertise with NCSM’s strong patient support infrastructure, we hope to reduce the financial burden and improve treatment continuity for underserved populations.”
Strengthening Biocon’s Commitment to Malaysian Healthcare
Biocon Biologics has already played an active role in Malaysia’s healthcare sector, previously supporting over 345,000 diabetes patients through its affordable treatment programs. With this new focus on oncology, the company is broadening its commitment to patient-centric, inclusive healthcare solutions in the country.
Headquartered in Bengaluru, India, Biocon Biologics operates in more than 120 countries, developing and delivering biosimilars for chronic diseases such as cancer, diabetes, and autoimmune disorders. The company has successfully launched nine biosimilars globally and is actively developing over 20 additional products across multiple therapeutic areas.
Expanding Global Partnerships
In addition to its new initiative in Malaysia, Biocon Biologics continues to grow its global footprint. Recently, the company partnered with Civica to improve access to Insulin Aspart in the United States, further advancing its mission of delivering affordable care worldwide.